United States Biotechnology & Medical Research

Track

Anthera Pharmaceuticals Inc (ANTH)

Track

Not featured in screeners

Featured in screeners

Not featured in screeners

Stock chart

Ticker: ANTH Exchange: OTC

Subscribe to get access to the transaction volume chart and in-chart transaction details

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Top insiders

Company data & Insiders

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results Settings

Trades

THOMPSON JOHN CRAIG

President & CEO

1 purchase — total 11,286 USD

Buy 20 Sep 2017

Value US$1,842,585.83 | Price 424.26 | Shares 98,633

TRUEX PAUL F

1 purchase — total 6,700 USD

Buy 7 Sep 2017

Value US$3,455,944.61 | Price 351.45 | Shares 13,416

Hislop Colin

Chief Medical Officer

1 sale — total 66,341 USD

Planned sale 13 Nov 2015

Value US$66,341.25 | Price 5.31 | Shares 12,500

Hislop Colin

Chief Medical Officer

1 sale — total 26,900 USD

Sale 11 Nov 2015

Value US$26,900.00 | Price 5.38 | Shares 5,000

Thompson David E.

1 purchase — total 53,000 USD

Buy 24 Jun 2013

Value US$53,000.00 | Price 0.53 | Shares 100,000

DZIURZYNSKI BOGDAN

1 purchase — total 5,900 USD

Buy 31 May 2013

Value US$5,900.00 | Price 0.59 | Shares 10,000

ORBIMED ADVISORS LLC

1 purchase — total 3,762,000 USD

Buy 30 Jan 2013

Value US$3,762,000.00 | Price 0.66 | Shares 5,700,000

ORBIMED ADVISORS LLC

1 purchase — total 1,142,481 USD

Buy 25 Jan 2013

Value US$1,142,480.80 | Price 0.65 | Shares 1,762,000

ORBIMED ADVISORS LLC

1 sale — total 942,071 USD

Sale 29 Jun 2012

Value US$942,070.53 | Price 0.73 | Shares 1,283,300

HENNEY CHRISTOPHER S

2 purchases — total 149,860 USD

Buy 29 Jun 2012

Value US$74,930.00 | Price 0.75 | Shares 100,000

Buy 29 Jun 2012

Value US$74,930.00 | Price 0.75 | Shares 100,000

TRUEX PAUL F

President and CEO

1 purchase — total 15,200 USD

Buy 29 Jun 2012

Value US$15,200.00 | Price 0.76 | Shares 20,000

ORBIMED ADVISORS LLC

1 sale — total 3,140,131 USD

Sale 22 Mar 2012

Value US$3,140,130.77 | Price 2.40 | Shares 1,306,700

ORBIMED ADVISORS LLC

1 sale — total 358,313 USD

Sale 21 Mar 2012

Value US$358,312.50 | Price 2.87 | Shares 125,000

ORBIMED ADVISORS LLC

1 sale — total 338,638 USD

Sale 20 Mar 2012

Value US$338,638.24 | Price 2.90 | Shares 116,800

HEALY JAMES

3 sales — total 155,625 USD

Sale 30 Dec 2011

Value US$1,743.00 | Price 6.23 | Shares 280

Sale 30 Dec 2011

Value US$25,460.25 | Price 6.23 | Shares 4,090

Sale 30 Dec 2011

Value US$128,421.75 | Price 6.23 | Shares 20,630

SOFINNOVA VENTURE PARTNERS VI L P

2 sales — total 27,203 USD

Sale 30 Dec 2011

Value US$1,743.00 | Price 6.23 | Shares 280

Sale 30 Dec 2011

Value US$25,460.25 | Price 6.23 | Shares 4,090

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Value
2017-09-20	2017-09-20	B Purchase	THOMPSON JOHN CRAIG President & CEO	98,633 +48.6% 424.26 US$1,842,586	98,633 +48.6%	424.26	US$1,842,586
2017-09-07	2017-09-07	B Purchase	TRUEX PAUL F	13,416 +12.1% 351.45 US$3,455,945	13,416 +12.1%	351.45	US$3,455,945
2015-11-18	2015-11-13	PlS Planned sale	Hislop Colin Chief Medical Officer Officer	87,810 -28.3% 376.35 US$3,798,842	87,810 -28.3%	376.35	US$3,798,842
2015-11-12	2015-11-11	S Sale	Hislop Colin Chief Medical Officer Officer	5,000 -20.7% 5.38 US$26,900	5,000 -20.7%	5.38	US$26,900
2013-06-26	2013-06-24	B Purchase	Thompson David E. Non-Executive Director	100,000 +354.6% 0.53 US$53,000	100,000 +354.6%	0.53	US$53,000
2013-06-04	2013-05-31	B Purchase	DZIURZYNSKI BOGDAN Non-Executive Director	10,000 +inf% 0.59 US$5,900	10,000 +inf%	0.59	US$5,900
2013-02-01	2013-01-30	B Purchase	ORBIMED ADVISORS LLC Non-Executive Director	5,700,000 +323.5% 0.66 US$3,762,000	5,700,000 +323.5%	0.66	US$3,762,000
2013-01-29	2013-01-25	B Purchase	ORBIMED ADVISORS LLC Non-Executive Director	1,762,000 +inf% 0.65 US$1,142,481	1,762,000 +inf%	0.65	US$1,142,481
2012-07-03	2012-06-29	S Sale	ORBIMED ADVISORS LLC Non-Executive Director	1,283,300 -100.0% 0.73 US$942,071	1,283,300 -100.0%	0.73	US$942,071
2012-07-02	2012-06-29	B Purchase	HENNEY CHRISTOPHER S Non-Executive Director	100,000 +inf% 0.75 US$74,930	100,000 +inf%	0.75	US$74,930
2012-07-02	2012-06-29	B Purchase	HENNEY CHRISTOPHER S Non-Executive Director	100,000 +97.6% 0.75 US$74,930	100,000 +97.6%	0.75	US$74,930
2012-07-02	2012-06-29	B Purchase	TRUEX PAUL F President and CEO Executive Director	20,000 +3.2% 0.76 US$15,200	20,000 +3.2%	0.76	US$15,200
2012-03-22	2012-03-22	S Sale	ORBIMED ADVISORS LLC Non-Executive Director	1,306,700 -50.5% 2.40 US$3,140,131	1,306,700 -50.5%	2.40	US$3,140,131
2012-03-22	2012-03-21	S Sale	ORBIMED ADVISORS LLC Non-Executive Director	125,000 -4.6% 2.87 US$358,312	125,000 -4.6%	2.87	US$358,312
2012-03-22	2012-03-20	S Sale	ORBIMED ADVISORS LLC Non-Executive Director	116,800 -4.1% 2.90 US$338,638	116,800 -4.1%	2.90	US$338,638
2012-01-03	2011-12-30	S Sale	HEALY JAMES Non-Executive Director Large shareholder	280 -0.6% 6.23 US$1,743	280 -0.6%	6.23	US$1,743
2012-01-03	2011-12-30	S Sale	HEALY JAMES Non-Executive Director Large shareholder	4,090 -0.6% 6.23 US$25,460	4,090 -0.6%	6.23	US$25,460
2012-01-03	2011-12-30	S Sale	SOFINNOVA VENTURE PARTNERS VI L P Large shareholder	280 -0.6% 6.23 US$1,743	280 -0.6%	6.23	US$1,743
2012-01-03	2011-12-30	S Sale	SOFINNOVA VENTURE PARTNERS VI L P Large shareholder	4,090 -0.6% 6.23 US$25,460	4,090 -0.6%	6.23	US$25,460
2012-01-03	2011-12-30	S Sale	HEALY JAMES Non-Executive Director Large shareholder	20,630 -0.6% 6.23 US$128,422	20,630 -0.6%	6.23	US$128,422